Tirzepatide
GLP-1Overview
A dual GIP/GLP-1 receptor agonist studied for weight management, glycemic control and metabolic health.
Mechanism of Action
Tirzepatide is a synthetic peptide studied as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In preclinical and translational research, it is understood to enhance glucose-dependent insulin secretion, reduce glucagon signaling, and influence appetite and gastric emptying, which may support improved metabolic regulation.
Reported Research Observations
In research settings, tirzepatide has been studied for weight management, glycemic control, and broader metabolic health. Researchers have observed improvements in markers related to glucose regulation and body weight in clinical and preclinical contexts, although outcomes depend on study design and population.
Quick Facts
- Commonly Available Vial Sizes
- 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 100 mg, 110 mg, 120 mg
- Typical Research Dose
- 2,500 – 15,000 mcg (2.5 – 15 mg)
- Suggested BAC Water
- 1 mL
- Category
- GLP-1
Safety & Handling
Tirzepatide is intended for research-use-only and should be handled according to laboratory safety procedures. For experimental work, it is commonly reconstituted with bacteriostatic water when appropriate for the protocol and stored refrigerated under conditions that limit contamination and degradation; investigators should follow the product-specific documentation and institutional guidance.
Notes
Available in 5mg to 120mg vials | Dosing: Once weekly, Ongoing (chronic therapy). Route: Subcutaneous (SC)
Commonly Researched Together
Further Reading
For laboratory and research use only. Not for human consumption or clinical use. Information is provided for reference and does not constitute medical advice.